Accelerometry Assessment of Factors Related to how TAK-861 Affects Disrupted Sleep in People with Narcolepsy Type 1

In episode 5, the sleep specialists examine actigraphy data from a study of TAK-861 in narcolepsy type 1 and discuss the promise of home-based sleep tracking in clinical care. [WATCH TIME: 3 minutes]:

Source: Neurology Read More

Previous PostIndirect Comparison Study Hints at Lower ARIA and ICH-Related Mortality Risk in Lecanemab Over Donanemab
Next PostPatient Case: Treatment Options for Advanced Parkinson Disease

Accelerometry Assessment of Factors Related to how TAK-861 Affects Disrupted Sleep in People with Narcolepsy Type 1

Previous PostIndirect Comparison Study Hints at Lower ARIA and ICH-Related Mortality Risk in Lecanemab Over Donanemab

Next PostPatient Case: Treatment Options for Advanced Parkinson Disease

Related Posts

<![CDATA[Telitacicept Moves Forward in Global Phase 3 Study for Generalized Myasthenia Gravis]]>

<![CDATA[Once-Daily Alixorexton Improves Cognition, Fatigue, and Disease Severity in Phase 2 Narcolepsy Type 1 Study]]>

<![CDATA[NMOSD Associated With Escalation to Rituximab, Elecsys NfL Test Receives European Approval, Neurology by the Numbers]]>

Categories